Real-World Evidence in Clinical Trials 2026: EHR Data, RWD Regulatory Acceptance, and Hybrid Study Designs

Real-world evidence has shifted from a supplement to randomized trial data to a genuine regulatory input — the FDA's 2023 framework for using electronic health record data in regulatory decisions marked a significant shift in what counts as evidence. The practical implications are still being worked out: which outcomes can be reliably captured from EHR data, how to handle confounding in observational studies, and when hybrid study designs (randomized assignment with real-world follow-up) are acceptable to regulators. For investigators, understanding these frameworks is increasingly essential; for patients, it means that data generated during their standard care is actively being used to answer research questions.

RWD Sources and Their Regulatory Standing

Not all real-world data sources carry equal regulatory weight. The FDA's RWE framework (published under 21st Century Cures Act Section 3022) evaluates RWD sources on two dimensions: data relevance (does it capture the right outcomes for the research question?) and data reliability (is it complete, accurate, and consistently collected?).

Hybrid Trial Designs: External Controls and Synthetic Arms

For rare diseases where a randomized placebo arm is scientifically or ethically problematic, hybrid designs use an external control constructed from RWD. Key approaches:

• Natural history studies as external controls: Pre-prospectively collected data on untreated patients with the same condition — enrolled before the investigational drug became available — serve as the comparator arm. The FDA has accepted natural history external controls in several rare pediatric disease approvals.
• Synthetic control arms (SCAs): Patient-level data from registries or EHRs are used to construct a matched control group using propensity score matching or Bayesian borrowing methods. SCAs reduce required sample size and eliminate the ethical burden of randomizing patients to no treatment, but require prospective agreement with regulators on the matching algorithm before study initiation.
• Single-arm trials with RWD comparators: For oncology indications with high unmet need, the FDA has granted accelerated approval to single-arm trials where historical RWD established a robust expected response rate. The investigational treatment must demonstrably exceed this threshold.

The Regulatory Threshold for RWE-Supported Approval

The FDA has approved or accepted RWE as primary or supportive evidence in a growing number of submissions. The pattern of acceptance reveals the key factors regulators evaluate:

• Pre-specified analysis plan: RWE used for regulatory purposes must have a fully pre-specified statistical analysis plan, registered before data lock. Post-hoc RWE analyses are not accepted as primary evidence.
• Fit-for-purpose data quality: Sponsors must document data provenance, completeness rates, and any known biases in the RWD source — and demonstrate these do not materially affect the primary endpoint estimate.
• Regulatory consultation: The FDA strongly recommends — and in practice requires — a Type B meeting before any submission relying on RWE as primary evidence. EMA provides similar pre-submission guidance through the PRIME and Regulatory Science to Innovation (RSI) pathways.